BIM 23244

Drug Profile

BIM 23244

Latest Information Update: 04 May 2007

Price : $50

At a glance

  • Originator Biomeasure Inc; Institut Federatif Jean Roche
  • Class
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acromegaly

Most Recent Events

  • 20 Jan 2003 No development reported - Preclinical for Acromegaly in USA (unspecified route)
  • 20 Jan 2003 No development reported - Preclinical for Acromegaly in France (unspecified route)
  • 31 Jan 2001 Preclinical development for Acromegaly in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top